Publication Cover
Inhalation Toxicology
International Forum for Respiratory Research
Volume 26, 2014 - Issue 14
172
Views
11
CrossRef citations to date
0
Altmetric
Research Article

The safety of ethambutol dihydrochloride dry powder formulations containing chitosan for the possibility of treating lung tuberculosis

, &
Pages 908-917 | Received 16 Aug 2014, Accepted 08 Oct 2014, Published online: 04 Dec 2014

References

  • Ahmad MI, Ungphaiboon S, Srichana T. (2014). The development of dimple-shaped chitosan carrier for ethambutol dihydrochloride dry powder inhaler. Drug Dev Ind Pharm Early online: 1–10.[Epub ahead of print]
  • Bai S, Gupta V, Ahsan F. (2010). Inhalable lactose-based dry powder formulations of low molecular weight heparin. J Aerosol Med Pulm Drug Deliv 23:97–104
  • Changsan N, Nilkaeo A, Pungrassami P, Srichana T. (2009). Monitoring safety of liposomes containing rifampicin on respiratory cell lines and in vitro efficacy against Mycobacterium bovis in alveolar macrophages. J Drug Target 17:751–62
  • Chuealee R, Aramwit P, Noipha K, Srichana T. (2011). Bioactivity and toxicity studies of amphotericin B incorporated in liquid crystals. Eur J Pharm Sci 43:308–17
  • Ghebreyesus TA, Kazatchkine M, Sidibe M, Nakatani H. (2010). Tuberculosis and HIV: time for an intensified response. Lancet 375:1757–8
  • Grenha A, Grainger CI, Dailey LA, et al. (2007). Chitosan nanoparticles are compatible with respiratory epithelial cells in vitro. Eur J Pharm Sci 31:73–84
  • Grenha A, Remunan-Lopez C, Carvalho EL, Seijo B. (2008). Microspheres containing lipid/chitosan nanoparticles complexes for pulmonary delivery of therapeutic proteins. Eur J Pharm Biopharm 69:83–93
  • Hasenbosch RE, Alffenaar JWC, Koopmans SA, et al. (2008). Ethambutol-induced optical neuropathy: risk of overdosing in obese subjects. Int J Tuberc Lung Dis 12:967–71
  • Huttunen K, Ruotsalainen M, Iivanainen E, et al. (2000). Inflammatory responses in RAW 264.7 macrophages caused by mycobacteria isolated from moldy houses. Environ Toxicol Pharmacol 8:237–44
  • Kaialy W, Martin GP, Larhrib H, et al. (2012). The influence of physical properties and morphology of crystallised lactose on delivery of salbutamol sulphate from dry powder inhalers. Colloids Surf B 89:29–39
  • Kanchan V, Panda AK. (2010). Interactions of antigen-loaded polylactide particles with macrophages and their correlation with the immune response. Biomaterials 28:5344–57
  • Kean T, Thanou M. (2010). Biodegradation, biodistribution and toxicity of chitosan. Adv Drug Deliv Rev 62:3–11
  • Kudsiova L, Lawrence MJ. (2008). A comparison of the effect of chitosan and chitosan-coated vesicles on monolayer integrity and permeability across Caco-2 and 16HBE14o-cells. J Pharm Sci 97:3998–4010
  • Muttil P, Wang C, Hickey AJ. (2009). Inhaled drug delivery for tuberculosis therapy. Pharm Res 26:2401–16
  • Palomini JC, Martin A, Camacho M, et al. (2002). Resazurin microtitre assay plate: simple and inexpensive method for detection of drug resistance in Mycobacterium tuberculosis. Antimicrob Agents Chemother 46:2720–2
  • Pandey R, Khuller GK. (2005). Antitubercular inhaled therapy: opportunities, progress, and challenges. J Antimicrob Chemother 55:430–5
  • Parikh R, Patel L, Dalwadi S. (2013). Microparticles of rifampicin: comparison of pulmonary route with oral route for drug uptake by alveolar macrophages, phagocytosis activity, and toxicity study in albino rats. Drug Deliv 21:406–11
  • Punturee K, Wild CP, Vinitketkumneun U. (2004). Thai medicinal plants modulate nitric oxide and tumor necrosis factor in J774.2 mouse macrophage. J Ethnopharmacol 95:183–9
  • Rabea EI, Badawy MET, Stevens CV, et al. (2003). Chitosan as Antimicrobial agent: applications and mode of action. Biomacromolecules 4:1457–65
  • Richardson SC, Kolbe HV, Duncan R. (1999). Potential of low molecular mass chitosan as a DNA delivery system: biocompatibility, body distribution and ability to complex and protect DNA. Int J Pharm 178:231–43
  • Rojanarat W, Nakpheng T, Thawithong E, et al. (2012). Levofloxacin-proliposomes: opportunities for use in lung tuberculosis. Pharmaceutics 4:385–412
  • Verschraegen CF, Gilbert BE, Loyer E, et al. (2004). Clinical evaluation of the delivery and safety of aerosolized liposomal 9-Nitro-20(S)-Camptothecin in patients with advanced pulmonary-malignancies. Clin Cancer Res 10:2319–26
  • Vinsova J, Vavrikova E. (2008). Recent advances in drugs and prodrugs design of chitosan. Curr Pharm Design 14:1311–26
  • WHO. (2011). Global tuberculosis control, Vol. 2. Geneva: WHO,9–27
  • Xie P, Zeng P, Wiedmann TS. (2008). Disease guided optimization of the respiratory delivery of microparticulate formulations. Expert Opin Drug Deliv 5:269–89
  • Yadav AB, Sharma R, Muttil P, et al. (2009). Inhalable microparticles containing isoniazid and rifabutin target macrophages and ‘stimulate the phagocyte’ to achieve high efficacy. Indian J Exp Biol 47:469–74
  • Yang F, Cui X, Yang X. (2002). Interaction of low-molecular-weight chitosan with mimic membrane studied by electrochemical methods and surface plasmon resonance. Biophys Chem 99:99–106

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.